Linked Life Data

18214362

Source:http://linkedlifedata.com/resource/pubmed/id/18214362

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-1-24
pubmed:abstractText
The pathophysiology and the treatment of diseases with clinical presentation so different as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis vulgaris have been revolutionized by the discovery of common pro-inflammatory effector mechanisms involving TNF-alpha and by the use of targeted therapies, the anti-TNF-alpha antibodies. In the past 10 years, our experience has helped several hundreds of patients who were treated with novel drugs, years before they became routinely available. In parallel tools of metrology were developped that can now be applied to the routine patient. Lastly, clinical research on these new drugs has also generated derived research works allowing the university hospital to satisfactorilly fullfil its specific missions.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0370-629X
pubmed:author
pubmed:issnType
Print
pubmed:volume
62 Spec No
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
55-62
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Biological therapy of inflammatory diseases].
pubmed:affiliation
Service de Rhumatologie, CHU Sart Tilman, Liège, Belgique.
pubmed:publicationType
Journal Article, English Abstract, Review